In contrast, the phosphomimetic Ser88 to aspartic acid (S88D) mutation showed a clear enhanced interaction with DNA end-resection enzymes such as MRE11 in ovarian cancer [45]. This evidence concerns the gene MRE11 and ovarian carcinoma.